![Upendra K. Marathi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Upendra K. Marathi
Chief Executive Officer at 7 Hills Pharma LLC
Upendra K. Marathi active positions
Companies | Position | Start | End |
---|---|---|---|
7 Hills Pharma LLC
![]() 7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Chief Executive Officer | - | - |
Founder | - | - | |
President | - | - |
Career history of Upendra K. Marathi
Former positions of Upendra K. Marathi
Companies | Position | Start | End |
---|---|---|---|
BCM Technologies, Inc.
![]() BCM Technologies, Inc. Investment ManagersFinance BCM Technologies Inc (BCM Technologies) is a venture capital subsidiary of Baylor University founded in 1983. The firm is headquartered in Houston, Texas. | Corporate Officer/Principal | - | - |
PLx Pharma, Inc. /Old/
![]() PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Corporate Officer/Principal | - | - |
Rice University | Corporate Officer/Principal | - | - |
MediGen Group LLC
![]() MediGen Group LLC Investment ManagersFinance Founded in 2001 by Ronald Zimmerman, MediGen Group LLC is a venture capital firm located in Houston, Texas | Private Equity Investor | - | - |
Training of Upendra K. Marathi
Loyola University of Chicago | Doctorate Degree |
Rice University | Masters Business Admin |
Statistics
International
United States | 7 |
Operational
Corporate Officer/Principal | 3 |
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Sectoral
Finance | 3 |
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
MediGen Group LLC
![]() MediGen Group LLC Investment ManagersFinance Founded in 2001 by Ronald Zimmerman, MediGen Group LLC is a venture capital firm located in Houston, Texas | Finance |
PLx Pharma, Inc. /Old/
![]() PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
BCM Technologies, Inc.
![]() BCM Technologies, Inc. Investment ManagersFinance BCM Technologies Inc (BCM Technologies) is a venture capital subsidiary of Baylor University founded in 1983. The firm is headquartered in Houston, Texas. | Finance |
7 Hills Pharma LLC
![]() 7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Upendra K. Marathi
- Experience